AlloVir Q2 net loss $45.3M; cash $246.5M; three Phase 3 trials on track for H2 2024 data

Kalaris Therapeutics, Inc.

2023-Q2 EPS reported -$0.92

Net loss of $45.3M ($0.48 per share) vs $44.6M ($0.69) in Q2 2022.
Cash, equivalents, and short-term investments $246.5M as of June 30, 2023.
Closed public offering with gross proceeds ~$75M, extending cash runway into 2025.
Three Phase 3 registrational trials of posoleucel in allo-HCT patients; data expected H2 2024.
FY 2023 operating expense guidance $150M-$170M excluding non-cash items.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kalaris Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income net loss was $45.3 million or $0.48 per share, EPS $0.48 per share. Guidance reaffirmed.

Period: the quarter ended June 30, 2023
Net income: net loss was $45.3 million or $0.48 per share
EPS: $0.48 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

For the quarter ended June 30, 2023, net loss was $45.3 million or $0.48 per share compared with a net loss of $44.6 million or $0.69 per share for the quarter ended June 30, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-202285

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.